Real-world treatment patterns in patients with chronic rhinosinusitis with nasal polyps who initiated dupilumab: A US claims analysis.

ABSTRACT:

Background

Dupilumab was approved as an add-on maintenance treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps based on the pivotal phase 3 trials.

Objective

Our aim was to assess patients' adherence to and persistence with dupilumab treatment in a real-world setting.

Methods

Patients aged 18 to 64 years who initiated dupilumab treatment between June 26, 2019, and December 31, 2021, were identified by using the IQVIA PharMetrics Plus claims database. Patients were required to have at least 12 months of continuous enrollment (baseline period) before the first recorded dispensing of dupilumab and at least 1 diagnosis of chronic rhinosinusitis with nasal polyps during the baseline period. Follow-up was censored at health pla

SUBMITTER: Pinto JM 

PROVIDER: S-EPMC12629711 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature